Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line

CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Chung Hyo, Kim, Yeongrin, Lee, Heung Kyoung, Lee, So Myoung, Jeong, Hye Gwang, Choi, Sang Un, Park, Chi Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730610/
https://www.ncbi.nlm.nih.gov/pubmed/33271901
http://dx.doi.org/10.3390/ijms21239163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730610/
https://www.ncbi.nlm.nih.gov/pubmed/33271901
http://dx.doi.org/10.3390/ijms21239163

Ejemplares similares